Literature DB >> 3885730

Hemodialysis-associated platelet activation and thrombocytopenia.

R M Hakim, A I Schafer.   

Abstract

The interactions between platelets and dialysis membranes were studied prospectively in 10 patients undergoing long-term stable dialysis. Transient but significant thrombocytopenia and platelet activation were found during dialysis with the commonly used cuprophane membrane. Platelet counts decreased from 231 +/- 21 X 10(3)/mm3 before dialysis to 127 +/- 28 X 10(3)/mm3 at 90 minutes following initiation of dialysis (p less than or equal to 0.007). Thromboxane B2, an index of platelet activation, also increased from a baseline level of 1.06 +/- 0.2 pg/10(6) platelets to 7.3 +/- 3.0 pg/10(6) platelets at 90 minutes (p less than or equal to 0.04). Cuprophane membranes were also shown to induce complement activation with C3a desArg, the stable derivative of C3 activation, showing a threefold increase from baseline 15 minutes after initiation of dialysis. In contrast, during dialysis with a non-complement-activating dialyzer membrane, polymethylmethacrylate, thrombocytopenia and platelet activation were not observed. These data suggest that platelet activation and thrombocytopenia during hemodialysis are associated with complement activation during hemodialysis in a manner similar to dialysis-associated neutropenia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3885730     DOI: 10.1016/0002-9343(85)90398-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Antiplatelet agents in hemodialysis.

Authors:  Massimiliano Migliori; Vincenzo Cantaluppi; Alessia Scatena; Vincenzo Panichi
Journal:  J Nephrol       Date:  2016-12-08       Impact factor: 3.902

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

3.  Influence of prostacyclin infusion on haemodialysis efficiency and blood cells.

Authors:  M Kuźniewski; W Sułowicz
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

4.  Thrombopoietic status of patients on haemodialysis.

Authors:  Taha Bat; Betul E Bat; Ahmed El-Moghraby; Samir Patel; Xingmin Feng; Cynthia E Dunbar; Erdal Sarac
Journal:  Br J Haematol       Date:  2016-02-16       Impact factor: 6.998

5.  Changes in platelet membrane glycoproteins and platelet-leukocyte interaction during hemodialysis.

Authors:  M Gawaz; C Bogner
Journal:  Clin Investig       Date:  1994-06

6.  Recurrent white thrombi formation in hemodialysis tubing: a case report.

Authors:  Kiran P Sathe; Wee-Song Yeo; Isaac Desheng Liu; Sudha Ekambaram; Mohammed Azar; Hui-Kim Yap; Kar-Hui Ng
Journal:  BMC Nephrol       Date:  2015-01-15       Impact factor: 2.388

7.  Section 5: Dialysis Interventions for Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

8.  Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases.

Authors:  Justin Lee; Ryan McMillan; Leonidas Skiadopoulos; Vinod Bansal; José Biller; Debra Hoppensteadt; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2018-11-14       Impact factor: 2.389

9.  Index Digit Necrosis as a Complication of Radial Artery Cannulation.

Authors:  Hesham R Alokaili; Tanveer A Bhat; Tareg M Alhablany; Tuqa A Alsinan; Duaa N Almansour; Felwa A AlMarshad; Abdulla Altamimi; Mohamed Ouhlous; Jawad Alnaqaa
Journal:  Cureus       Date:  2022-08-27

10.  Thrombocytopenia in the setting of hemodialysis using biocompatible membranes.

Authors:  Kathryn B Muir; Clifford D Packer
Journal:  Case Rep Med       Date:  2012-10-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.